Department of Surgery, Texas Tech HSC Paul Foster School of Medicine, El Paso, TX, 79903, USA.
Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Obes Surg. 2023 Mar;33(3):720-724. doi: 10.1007/s11695-023-06452-2. Epub 2023 Jan 18.
INTRODUCTION/PURPOSE: One anastomosis gastric bypass (OAGB) and single anastomosis duodenoileostomy with sleeve (SADI-S) are two highly effective bariatric procedures that have been recently endorsed by the American Society of Metabolic and Bariatric Surgery (ASMBS). We compared the outcomes and safety profiles of SADI-S and OAGB using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) database.
Retrospective analysis on patients who underwent SADI-S or OAGB obtained from the MBSAQIP database 2020-2021. Patients who underwent concurrent procedures (besides EGD) or had missing data were removed. Variables included age, sex, body mass index, American Society of Anesthesiologists (ASA) class, and pertinent medical comorbidities. Data were analyzed for 30-day postoperative morbidity, mortality, reoperation, reintervention, and readmissions. p values were calculated using Student's t-test or Fisher analysis.
A total of 694 and 1068 patients respectively underwent SADI-S or OAGB. Statistically significant comorbidities included age (42.2 ± 10.8 vs. 43.7 ± 12.2), BMI (50.6 ± 9.1 vs. 45.3 ± 7.1), ASA 2 (66 (9.5%) vs. 165 (15.4%)), ASA 4 [69 (9.9%) vs. 20 (1.9%)], and immunosuppressive therapy [24 (3.5%) vs. 17 (1.6%)]. Clavien-Dindo-based analysis highlighted that SADI-S had higher grade 2 (p = 0.005) and grade 4b (p = 0.001) complications. Patients who underwent SADI-S were twice as likely to be readmitted within 30 days (3.7% vs. 1.9%; p = 0.021).
SADI-S had higher readmission rates and higher Clavien-Dindo grade 2 and 4b complications. To note, SADI-S patients had higher BMIs. Further studies are needed to determine the long-term complications and efficacy of both operations.
简介/目的:单吻合口胃旁路术(OAGB)和单吻合口十二指肠空肠旁路术加袖状胃切除术(SADI-S)是两种高效的减重手术,最近已被美国代谢和减重外科学会(ASMBS)认可。我们使用代谢和减重外科学会认证和质量改进计划(MBSAQIP)数据库比较了 SADI-S 和 OAGB 的结果和安全性。
回顾性分析了 2020 年至 2021 年期间从 MBSAQIP 数据库中接受 SADI-S 或 OAGB 的患者。去除了同时进行其他手术(除内镜检查外)或数据缺失的患者。变量包括年龄、性别、体重指数、美国麻醉医师协会(ASA)分级和相关的医学合并症。分析了 30 天术后发病率、死亡率、再次手术、再次干预和再入院情况。使用学生 t 检验或 Fisher 分析计算 p 值。
分别有 694 例和 1068 例患者接受了 SADI-S 或 OAGB。具有统计学意义的合并症包括年龄(42.2±10.8 岁比 43.7±12.2 岁)、体重指数(50.6±9.1 千克/平方米比 45.3±7.1 千克/平方米)、ASA 2 级(66 例[9.5%]比 165 例[15.4%])、ASA 4 级[69 例[9.9%]比 20 例[1.9%])和免疫抑制治疗[24 例[3.5%]比 17 例[1.6%])。基于 Clavien-Dindo 的分析表明,SADI-S 的 2 级(p=0.005)和 4b 级(p=0.001)并发症更高。SADI-S 组患者在 30 天内再次入院的可能性是对照组的两倍(3.7%比 1.9%;p=0.021)。
SADI-S 的再入院率更高,Clavien-Dindo 2 级和 4b 级并发症更高。需要注意的是,SADI-S 患者的 BMI 更高。需要进一步研究以确定两种手术的长期并发症和疗效。